Table 1.
Baseline Clinical Features of ARVC/D Patients With an S‐ICD
| Clinical Variables | Overall Population (N=29) | Primary Prevention (n=17) | Secondary Prevention (n=12) |
|---|---|---|---|
| Demographics | |||
| Male | 15 (52) | 10 (53) | 5 (42) |
| White | 28 (97) | 16 (94) | 12 (100) |
| Proband | 22 (76) | 10 (59) | 12 (100) |
| Mutation carrier | 16/27 (59) | 11/16 (69) | 5/11 (45) |
| Age at ICD implantation, y | 34±15 | 32±15 | 38±16 |
| Height, cm | 170 (165–175) | 168 (164–175) | 173 (167–182) |
| Weight, lb | 155 (135–176) | 146 (132–165) | 168 (149–181) |
| BMI, kg/m2 | 24.32±3.42 | 23.43±3.48 | 25.59±3.01 |
| Clinical characteristics at implant | |||
| Syncope | 10 (34) | 5 (29) | 5 (42) |
| Inducibility at EPS | 7/17 (41) | 1/9 (11) | 6/8 (75) |
| ≥1000 PVCs on Holter monitoring | 15/22 (68) | 8/13 (62) | 7/9 (78) |
| Inverted T waves in ≥3 precordial leads | 24/28 (86) | 14/16 (88) | 10/12 (83) |
| QRS duration, ms | 92 (82–100) | 90 (83–99) | 92 (80–103) |
| NSVT | 10 (34) | 2 (12) | 8 (67) |
| Major RV structural abnormality on CMR | 21/27 (72) | 12/15 (80) | 9/12 (75) |
| RVEF, % | 41 (35–49) | 40 (33–46) | 44 (35–52) |
| LVEF, % | 56 (45–63) | 50 (45–63) | 58 (56–63) |
| Medications at implant | |||
| Any medication | 24 (83) | 14 (82) | 10 (83) |
| ACEi/ARB | 12 | 8 | 4 |
| β‐Blocker | 19 | 12 | 7 |
| Flecainide | 2 | … | 2 |
| Amiodarone | 1 | … | 1 |
| Sotalol | 1 | … | 1 |
Values are mean±SD, n (%), n/N (%), or median (interquartile range). ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARVC/D, arrhythmogenic right ventricular cardiomyopathy/dysplasia; BMI, body mass index; CMR, cardiac magnetic resonance; EPS, electrophysiology study; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; NSVT, nonsustained ventricular tachycardia; PVC, premature ventricular contraction; RV, right ventricular; RVEF, right ventricular ejection fraction; S‐ICD, subcutaneous implantable cardioverter‐defibrillator.